Nautilus Biotechnology Achieves Milestone with First External Field Evaluation Unit for Alzheimer's Research
Key Insights
Nautilus Biotechnology successfully installed and tested its first external field evaluation unit at the Buck Institute for Research on Aging, marking a critical milestone for single-molecule proteomics platform deployment.
The collaboration generated highly reproducible tau (search) proteoform data from neurodegenerative disease (search) samples over six months, providing external validation of the company's next-generation proteomics technology.
The proprietary tau (search) proteoform assay can quantify 768 proteoform groups, enabling unprecedented analysis of protein modifications that influence Alzheimer's disease (search) progression.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) and the Buck Institute for Research on Aging announced the successful installation and testing of Nautilus' first external field evaluation unit, representing a significant advancement in single-molecule proteomics technology for neurodegenerative disease (search) research. The collaboration has generated highly reproducible data from Alzheimer's disease (search) samples over more than six months of operation at the Buck Institute in the San Francisco Bay Area.
Platform Validation and Performance
The deployment marks a critical milestone in providing independent research laboratories with direct access to Nautilus' single-molecule proteomics platform. Researchers at the Buck Institute have successfully operated the instrument to generate tau (search) proteoform data, providing external validation of the company's next-generation proteomics technology.
"The results we have already generated on the Nautilus single-molecule proteomics instrument demonstrate robust platform performance, which will enable quantitative characterization of disease-associated proteins in order to understand the complex biology of aging and neurodegeneration (search)," said Birgit Schilling, Ph.D., Professor and Director of the Mass Spectrometry Center at the Buck Institute.
The unit employs Nautilus' Iterative Mapping approach and a proprietary tau (search) proteoform assay developed to quantify 768 proteoform groups. This capability enables high-resolution analysis of protein modifications that most strongly influence disease progression, particularly in Alzheimer's disease (search) and related neurodegenerative conditions.
Research Focus and Collaboration
The ongoing collaboration between Nautilus and the Buck Institute focuses on leveraging the Nautilus Proteome Analysis Platform to explore the role of tau (search) proteoforms—the numerous functional variants of the Alzheimer's-associated protein—in neurodegeneration (search) and cognitive decline. The joint research efforts have demonstrated that the tau assay generates highly reproducible end-to-end platform data across sites and users.
"Measuring tau (search) proteoforms at this unprecedented level will vastly expand our knowledge and means to study mechanisms underlying Alzheimer's disease (search) and related conditions," Schilling noted. The collaboration aims to accelerate broader research and development efforts to investigate severe conditions such as Alzheimer's disease.
Scientific Impact and Future Directions
The successful field evaluation establishes the instrument's qualification and readiness for broader research applications. According to Parag Mallick, Ph.D., co-founder and Chief Scientist of Nautilus, the collaboration has "swiftly built a strong foundation for next-generation proteomics studies to uncover actionable new insights into disease pathology."
The joint research results demonstrate high reproducibility across sites and provide insight into novel tau (search) biology, signaling what the companies describe as "a fundamental shift in how proteomics technology can advance human health and longevity."
Conference Presentation
Initial findings from the collaboration will be reported at the 2025 Human Proteome Organization (HUPO) World Congress in a seminar titled "Redefining Proteomics with Single-Molecule Iterative Mapping" on November 10, 2025, at 12:15 PM EDT in Toronto. The presentation will showcase the powerful data produced through the ongoing collaboration and the performance of Nautilus' first-ever field evaluation unit.
The successful deployment at the Buck Institute represents Nautilus' mission to democratize access to the proteome and enable fundamental advancements across human health and medicine, particularly in understanding complex disease biology associated with aging and neurodegeneration (search).